Shanghai LKtime Biotechnology Co., Ltd. (LKtime Biotech) warmly congratulates its client, Ab&B Bio-Tech CO., LTD. JS and its subsidiary Yither Biotechnology Co., Ltd. (Yither Biotech), on the approval of the Investigational New Drug (IND) application for their Class 1 innovative drug "Recombinant Herpes Zoster Vaccine (CHO Cell)" by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).

About Recombinant Herpes Zoster Vaccine

Herpes zoster (HZ) is an infectious disease primarily affecting the nerves and skin, caused by the reactivation of the varicella-zoster virus (VZV). Its hallmark clinical manifestations include band-like distributed clusters of blisters accompanied by significant neuropathic pain, with pain severity typically intensifying with age. The disease predominantly occurs in elderly individuals, immunocompromised patients, and those using immunosuppressive medications, and exhibits a certain recurrence rate. As no effective treatment currently exists for herpes zoster, vaccination serves as the primary and effective preventive measure against this condition. The recombinant zoster vaccine (CHO cell) represents a key prophylactic approach.